Does Blue Cross Blue Shield of Illinois Cover Trulicity?

What Is Trulicity and Why Does It Matter for BCBSIL Members?

Trulicity is the brand name for dulaglutide, a once-weekly injectable GLP-1 receptor agonist manufactured by Eli Lilly. The FDA approved it in September 2014 for glycemic control in adults with type 2 diabetes, and a subsequent label expansion added cardiovascular risk reduction for patients with established cardiovascular disease or multiple risk factors. In the REWIND trial (N=9,901), dulaglutide reduced the composite endpoint of major adverse cardiovascular events by 12% relative to placebo over a median 5.4 years (HR 0.88; 95% CI 0.79 to 0.99; P<0.026). That cardiovascular indication matters for insurance purposes because it strengthens the medical-necessity argument during prior authorization.

GLP-1 receptor agonists as a class have grown into one of the most prescribed drug categories in the United States. The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists as preferred add-on therapy for patients with type 2 diabetes who have established cardiovascular disease, chronic kidney disease, or a need for weight management beyond what metformin provides. Understanding how BCBSIL treats this class on its formulary is practical, not academic.

Dulaglutide works by mimicking endogenous GLP-1, stimulating glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying. It is available in four dose strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg per weekly injection. The 3 mg and 4.5 mg doses were approved in 2020 and offer additional A1C reduction for patients who need tighter glycemic control.

How BCBSIL Formularies Are Structured

Blue Cross Blue Shield of Illinois is the state's largest commercial insurer and operates under the Health Care Service Corporation (HCSC) umbrella. BCBSIL does not use a single formulary across all products. Each plan type has its own drug list, and the tier placement for any given drug can differ across:

• PPO plans (BlueChoice, Blue Advantage PPO)
• HMO plans (HMO Illinois, Blue Advantage HMO)
• Illinois state employee plans (State Employees Group Insurance Program, SEGIP)
• Medicare Advantage plans (BlueEdge, BlueMedicare)
• Marketplace / ACA exchange plans

Because formularies change annually each January 1, checking the specific plan's drug list at the BCBSIL member portal (bcbsil.com) or calling the member services number on the back of the insurance card is the only definitive way to confirm current coverage. Formulary lookups are also available through the pharmacy benefits manager that BCBSIL contracts with, which for most commercial lines has historically been Prime Therapeutics.

Specialty drugs like Trulicity typically fall into Tier 3 (preferred brand) or Tier 4 (non-preferred brand) on standard BCBSIL commercial formularies. The FDA defines specialty drugs as those requiring special handling, administration, or monitoring, and insurers routinely place them on higher tiers with cost-sharing that can reach 25-50% coinsurance. On a Tier 4 placement with 40% coinsurance and no deductible credit, a member could owe more than $390 per monthly fill at the list price.

Prior Authorization: What BCBSIL Typically Requires for Trulicity

Prior authorization (PA) is the single biggest obstacle most BCBSIL members face with Trulicity. Prior authorization is a formal process where your prescribing clinician submits clinical documentation to the insurer before the pharmacy will dispense the drug at the covered price.

BCBSIL's PA criteria for Trulicity are not publicly posted in full, but based on standard industry practice and published HCSC clinical policy documents, most BCBSIL plans require the following:

1. Confirmed diagnosis of type 2 diabetes mellitus (ICD-10 code E11.x). Trulicity is not approved for type 1 diabetes, and BCBSIL will not cover it for that indication.
2. Documentation of A1C level, typically above 7.0% or above the patient's individualized goal, showing inadequate glycemic control.
3. Step therapy: evidence that the patient has tried and failed at least one, and sometimes two, oral antidiabetic agents, most commonly metformin (unless contraindicated by eGFR <30 mL/min/1.73 m², lactic acidosis risk, or documented GI intolerance).
4. Prescriber specialty: some plans require that the prescription originate from or be co-signed by an endocrinologist or diabetologist, particularly for doses above 1.5 mg.
5. Cardiovascular indication add-on: for members with documented ASCVD, CKD stage 3 or higher, or multiple CV risk factors, the cardiovascular indication under the ADA 2024 Standards may help bypass step therapy requirements.

A PA approval, when granted, is typically valid for 12 months, after which re-authorization is required with updated A1C values and clinical notes.

The HealthRX Prior Authorization Readiness Framework for GLP-1 Coverage organizes the documentation your clinician needs into four buckets: (1) diagnosis substantiation, (2) trial-and-failure documentation, (3) current glycemic status, and (4) cardiovascular or renal comorbidity evidence. Preparing all four before the prescriber submits the PA can reduce round-trip delays from a median 14 days to under 5 business days in our clinical team's experience.

Step Therapy: Which Drugs Must Be Tried First?

Step therapy means the insurer requires a patient to try less expensive drugs before approving the requested drug. For Trulicity, BCBSIL's step therapy protocol on most commercial plans typically requires one or more of the following:

• Metformin (first-line, unless contraindicated)
• A sulfonylurea such as glipizide or glimepiride
• A DPP-4 inhibitor such as sitagliptin (Januvia) or alogliptin

The ADA notes that "for patients with type 2 diabetes and established cardiovascular disease, heart failure, or chronic kidney disease, medication with proven cardiovascular benefit should be used independent of baseline A1C," which is the clinical argument clinicians can use to request a step therapy exception when the cardiovascular or renal indication applies.

Illinois has a step therapy override law (215 ILCS 5/356z.45) that took effect in 2018. Under this law, a health plan must grant a step therapy exception when:

• The required drug is contraindicated or is expected to cause an adverse reaction
• The required drug has been tried and failed in the past
• The patient is currently stable on the requested drug after starting it through samples or another source
• The required drug is not clinically appropriate for the patient

An override request supported by clinical documentation from your prescriber has a meaningful chance of success, particularly if metformin is contraindicated or if the patient has established ASCVD.

What Does Trulicity Cost Under BCBSIL Coverage?

Out-of-pocket cost depends on the plan's specific cost-sharing structure, the formulary tier, whether the deductible has been met, and whether the patient qualifies for manufacturer savings programs.

Scenario A: Tier 3, deductible met A member on a standard BlueChoice PPO with Trulicity at Tier 3 and a $30-per-branded-drug copay after deductible would pay $30 per four-pen monthly supply once the annual deductible is satisfied.

Scenario B: Tier 4 with coinsurance, deductible not met A member on a high-deductible health plan (HDHP) paired with an HSA, with a $1,500 individual deductible and 30% coinsurance after that, could owe the full negotiated rate (often $700 to $900 per month) until the deductible is met, then 30% coinsurance thereafter.

Eli Lilly Savings Card For commercially insured patients who qualify, the Lilly Trulicity Savings Card can reduce the monthly cost to as low as $25 per month, with a maximum benefit of $150 per fill or $1,800 per calendar year. The card is not available to patients enrolled in Medicare, Medicaid, or other government programs. Enrollment is available at trulicity.com or through the prescribing pharmacy.

Patient Assistance Program Patients without insurance or whose income qualifies them may apply for Lilly Cares Foundation assistance. Income thresholds and program terms change annually, so direct contact with the Lilly Cares Foundation (1-800-545-5979) is the most accurate source.

How to Check Your Specific BCBSIL Plan Coverage

The most reliable steps to verify Trulicity coverage for your specific BCBSIL plan:

1. Log into the BCBSIL member portal at bcbsil.com. Use the drug formulary search tool. Enter "dulaglutide" or "Trulicity" and your plan name.
2. Call the pharmacy benefits number on the back of your insurance card. Ask specifically: (a) What tier is Trulicity on my plan? (b) Is prior authorization required? (c) Is step therapy required? (d) What is my cost-sharing after the deductible?
3. Ask your pharmacy to run a test claim before the first fill. The pharmacy's point-of-sale system will return the exact member cost-share in real time.
4. Request a formulary exception if Trulicity is not on the formulary at all. A prescriber must submit a letter of medical necessity explaining why alternative formulary drugs are not appropriate.

What to Do If BCBSIL Denies Trulicity Coverage

A denial is not the end of the road. Federal ACA rules and Illinois state insurance law provide multiple avenues to challenge a denial.

Step 1: Internal Appeal Under the ACA, you have the right to a full internal appeal within 180 days of receiving a denial notice. Your prescriber submits updated clinical records, peer-reviewed literature, and a letter of medical necessity. The ACA requires health plans to provide a written explanation of any adverse benefit determination and to allow internal appeals before any final determination.

Step 2: Expedited Review If a standard internal appeal timeline would seriously jeopardize your health, you can request an expedited review. BCBSIL must respond within 72 hours.

Step 3: External Independent Medical Review (IMR) If the internal appeal fails, you can request an external IMR through the Illinois Department of Insurance. An independent physician reviewer not affiliated with BCBSIL evaluates the clinical record. The Illinois Department of Insurance reports that external review decisions overturned the insurer's denial in approximately 40-45% of cases across all diagnoses in recent reporting years.

Step 4: Illinois Department of Insurance Complaint A formal complaint with the Illinois DOI (insurance.illinois.gov) creates a regulatory record and sometimes prompts a plan reconsideration faster than the formal appeal process.

Alternative GLP-1 Agents That May Be Preferred on BCBSIL Plans

If Trulicity specifically is denied or placed on a non-preferred tier, other GLP-1 receptor agonists may be covered at a lower tier on your BCBSIL plan. The clinical profiles of these agents overlap substantially:

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg weekly injectable) In the SUSTAIN-6 trial (N=3,297), semaglutide reduced major adverse cardiovascular events by 26% vs. placebo (HR 0.74; 95% CI 0.58 to 0.95). BCBSIL has placed Ozempic on a preferred specialty tier on certain commercial plans, making it a reasonable therapeutic alternative when Trulicity faces higher cost-sharing.

Victoza (liraglutide 1.2 mg, 1.8 mg daily injectable) LEADER (N=9,340) showed liraglutide reduced the three-point MACE composite by 13% vs. placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). Victoza has been on the market longer and may appear on BCBSIL formularies at a lower tier in some plan years.

Rybelsus (oral semaglutide 7 mg, 14 mg) For patients with injection reluctance, oral semaglutide is an option that some BCBSIL plans cover at a more favorable tier. Switching from Trulicity to Rybelsus requires a prescriber's clinical judgment about dose equivalence and glycemic targets.

Mounjaro (tirzepatide) for Type 2 Diabetes Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist, received FDA approval for type 2 diabetes in May 2022. Some BCBSIL commercial plans have added tirzepatide to the formulary. In SURPASS-2 (N=1,879), tirzepatide 15 mg reduced A1C by 2.46% vs. 1.86% for semaglutide 1 mg (P<0.001). If your clinical picture supports tirzepatide, it may warrant a formulary exception request even if Trulicity was denied.

How Cardiovascular Comorbidities Affect Coverage Decisions

BCBSIL, like most commercial insurers, follows the ADA-published clinical practice guidelines when evaluating GLP-1 prior authorization requests. The 2024 ADA Standards of Care explicitly state that GLP-1 receptor agonists with proven cardiovascular benefit should be prioritized for patients with:

• Established atherosclerotic cardiovascular disease (ASCVD)
• Heart failure with reduced or preserved ejection fraction
• Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
• High 10-year ASCVD risk score (>=20%)

For these patients, the cardiovascular indication creates a stronger medical necessity argument that may bypass standard step therapy. The prescriber's letter of medical necessity should explicitly cite the REWIND trial data and the ADA guideline recommendation, referencing the specific comorbidity documented in the patient's chart.

Medicare Advantage and Illinois Medicaid: Different Rules Apply

Medicare Advantage (BlueEdge, BlueMedicare) Medicare Advantage plans operated by BCBSIL follow CMS formulary regulations under Part D. Trulicity is covered under Part D (not Part B, since it is self-administered). Tier placement and PA criteria differ from commercial plans. The Lilly savings card does NOT apply to Medicare beneficiaries. The Extra Help (Low Income Subsidy) program through the Social Security Administration may reduce Part D costs for qualifying members. CMS Part D formulary requirements are governed by 42 CFR Part 423.

Illinois Medicaid (Medicaid Managed Care) BCBSIL administers some Illinois Medicaid managed care contracts. Medicaid formularies are separate from commercial formularies, and GLP-1 agents including Trulicity may face additional restrictions. The Illinois Department of Healthcare and Family Services (HFS) Preferred Drug List governs coverage for fee-for-service Medicaid members. As of 2024, GLP-1 agents on the Illinois HFS PDL require prior authorization and, for most plans, documented failure on metformin.

The HealthRX Clinical Approach to GLP-1 Access

Patients who come to HealthRX for GLP-1 prescriptions routinely face insurance barriers. Our clinical team's process:

1. Obtain the patient's current BCBSIL formulary PDF (updated each plan year).
2. Review the patient's diabetes history, A1C trajectory, and comorbidities.
3. Draft a prior authorization packet that includes: a Letter of Medical Necessity citing the ADA 2024 Standards of Care, REWIND or LEADER trial data where applicable, documentation of prior drug trials, and the patient's most recent A1C and eGFR.
4. Submit the PA and track the timeline. If not resolved in 15 business days, escalate to expedited review.
5. If denied, initiate the internal appeal simultaneously with an Illinois step therapy override request.

Most patients with a documented type 2 diabetes diagnosis, an A1C above target, and at least one prior drug trial receive PA approval on the first submission when documentation is complete. The cases that most often require appeals are those where step therapy documentation is missing or the prescriber letter is too brief.